Intellia Therapeutics announced that the U.S. Food and Drug Administration accepted its Biologics License Application for lonvo-z, granting Priority Review with a target action date of March 10, 2027. If approved, lonvo-z would become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for hereditary angioedema.
Hereditary angioedema (HAE) is a disease that can be responsible for profound disability and place patients at risk for fatal attacks. Lonvo-z attempts to alter this treatment paradigm fundamentally by modifying human genetics with a single dose.
In Plain English: The Clinical Takeaway
- What lonvo-z is: A single-dose, in vivo (inside the body) CRISPR gene editing candidate utilizing Nobel Prize-winning CRISPR/Cas9 technology to permanently lower kallikrein.
- How it works: The therapy targets and inactivates the kallikrein B1 (KLKB1) gene, effectively lowering kallikrein levels.
- What the data shows: In Phase 3 clinical trials, a single 50-milligram dose led to an 87% reduction in mean monthly attacks compared to placebo, freeing most patients from ongoing prophylactic medication.
Clinical Efficacy and Phase 3 Trial Architecture
The Biologics License Application is backed by robust data from Intellia’s global Phase 3 HAELO clinical trial. The study evaluated 80 adult and adolescent patients aged 16 years and older diagnosed with Type 1 or Type 2 HAE. Recruitment for the trial concluded rapidly, reaching full enrollment in just nine months.
The trial’s primary endpoint measured the reduction of swelling attacks during an efficacy evaluation period spanning weeks 5 to 28. According to clinical data, the 50-milligram dose of lonvo-z achieved an 87% reduction (p<0.0001) in mean monthly attacks compared to the placebo arm. Furthermore, 62% of patients who received lonvo-z experienced zero attacks and required no additional HAE therapy throughout the six-month evaluation period, contrasting sharply with 11% in the placebo group (p<0.0001).
As of the February 10, 2026 data cutoff, every patient who received lonvo-z at baseline or switched via crossover after week 28 remained entirely free from long-term prophylaxis therapy. “HAE is an unpredictable disease that can be responsible for profound disability and place patients at risk for fatal attacks,” said Joshua Jacobs, M.D., Medical Director at Allergy and Asthma Clinical Research, Inc., and a HAELO trial investigator. “Today’s announcement is exciting because it advances us one step closer to potentially having a one-time treatment option available for patients who continue to be burdened by this chronic disease.”
Safety Profiles and Regulatory Designations
Monitoring adverse events during the primary observation period revealed a favorable safety and tolerability profile for lonvo-z. Treatment-emergent adverse events occurring at a higher frequency in the active treatment group compared to placebo included infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infections. Clinical documentation confirms that all reported adverse events were mild or moderate in severity, with zero serious adverse events observed in the lonvo-z arm.
Lonvo-z has secured five notable regulatory designations, including Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. FDA, the Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Priority Medicines (PRIME) status.
| Trial Metric / Outcome | Lonvo-z Arm (50 mg) | Placebo Arm |
|---|---|---|
| Mean Monthly Attack Reduction | 87% reduction (p<0.0001) | Baseline reference |
| Attack-Free & Therapy-Free Rate (Weeks 5-28) | 62% of patients | 11% of patients |
| Most Common Mild/Moderate Adverse Events | Infusion reactions, headache, fatigue, back pain, URI | Standard baseline symptoms |
| Serious Adverse Events (SAEs) | 0 reported | 0 reported |
“Today marks an important milestone for the patients we are committed to serving and for Intellia’s pioneering work in the field of in vivo gene editing,” noted John Leonard, M.D., Intellia President and Chief Executive Officer. With the FDA deciding against holding an advisory committee meeting prior to the Prescription Drug User Fee Act target date of March 10, 2027, the path forward rests on the agency’s final review of the manufacturing, efficacy, and safety data packages.
Contraindications & When to Consult a Doctor
References
- U.S. Food and Drug Administration (FDA). Biologics License Application (BLA) Priority Review Guidelines and PDUFA Procedures. FDA PDUFA Overview
- MedlinePlus HAE Overview
- WHO Guidelines
Disclaimer: This article is published for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified physician regarding any questions about a medical condition or therapeutic options.
